文献速递骨质疏松与代谢性骨病

TRACP-5b监测骨质疏松抗骨吸收治疗的临床效用

The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis.
PubMed 文献 · Osteoporos Int · 2022-01-31

研究探讨进食对TRACP-5b的影响及其临床诊断准确性。进食不影响TRACP-5b,但使CTX和PINP分别降低29%和10%。TRACP-5b与CTX、PINP在唑来膦酸和地舒单抗组诊断准确性相似,但在口服双膦酸盐组存在显著差异。

要点

  • 进食后TRACP-5b水平无变化,而CTX和PINP分别显著降低29%和10%。
  • 唑来膦酸和地舒单抗组中,TRACP-5b与CTX、PINP的AUC无差异。
  • 口服双膦酸盐组中,TRACP-5b与PINP、CTX的AUC有显著差异。

核心结论

  • TRACP-5b不受进食影响,而CTX和PINP受进食影响。
  • 所有三种骨转换标志物均与腰椎和全髋骨密度变化相关。
  • TRACP-5b与CTX和PINP在常用骨质疏松治疗中诊断准确性相似,但口服双膦酸盐治疗除外。

研究设计与样本

  • 招募18例患者研究进食对骨转换标志物的影响。
  • 97例接受每年静脉注射唑来膦酸5mg的患者(平均年龄70岁)与97例未治疗患者作为组匹配对照。
  • 16例接受每6个月皮下注射地舒单抗60mg的患者(平均年龄76岁)与16例匹配对照。
  • 76例接受口服双膦酸盐治疗:70mg阿仑膦酸钠每周一次、35mg利塞膦酸钠和150mg伊班膦酸钠每月一次(4%)。
  • 80例未治疗患者作为组匹配对照。

主要发现

  • 进食后TRACP-5b水平无影响,CTX和PINP分别显著降低29%和10%(p < 0.001)。
  • 唑来膦酸和地舒单抗组中,TRACP-5b、PINP和CTX的AUC无差异。
  • 口服双膦酸盐组中,TRACP-5b与PINP的AUC显著不同(p < 0.01),TRACP-5b与CTX的AUC显著不同(p = 0.001)。
  • TRACP-5b与骨密度呈负相关。

局限性

  • 未确定依从性的估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: TRACP-5b can be used to monitor the response of treatments in osteoporosis. We investigated the effect of feeding on levels of TRACP-5b and how these markers perform in a clinical setting. After feeding, there was no effect on levels TRACP-5b. It has similar diagnostic accuracy to CTX and PINP. INTRODUCTION: Bone turnover markers (BTMs) can be used to monitor response to osteoporosis treatment. However, some are affected by food intake and are not suitable to measure in a clinical setting. An assay is available which is capable of detecting the active isoform 5b of tartrate resistance acid phosphatase (TRACP-5b) and it may have minimal biological variation. Our aims were to investigate the effect of feeding on levels of TRACP-5b and compare this to CTX and PINP and then to compare the diagnostic accuracy of TRACP-5b to CTX and PINP in patients with osteoporosis given commonly used treatments. METHODS: Eighteen patients were recruited to investigate the effect of feeding on BTMs. Ninety-seven patients (74 females and 23 males) receiving 5 mg annual intra-venous zoledronate (mean age 70) and 97 patients receiving no treatment were recruited as group-matched controls. Sixteen patients receiving 60 mg subcutaneous denosumab every 6 months, (mean age 76) and 16 matched controls were recruited. Seventy-six patients were receiving oral bisphosphonates: 70 mg alendronate weekly, 35 mg risedronate and 150 mg monthly ibandronate (4%). Thirty of these patients had BMD measured at the total hip and lumbar spine. An estimate of compliance was not determined. Eighty patients receiving no treatment were recruited as group-matched controls. TRACP-5b (ELISA, Nittobo) and CTX and PINP were measured in serum in the non-fasting state between 0800 and 1700. RESULTS: After feeding, there was no effect on levels TRACP-5b and significant reductions in CTX and PINP, 29% and 10%, respectively (p < 0.001). In the zoledronate and denosumab groups, there were no differences in the areas under the curves (AUCs) between TRACP-5b, PINP and CTX. In the oral bisphosphonates group, the AUCs between TRACP-5b and PINP and TRACP-5b and CTX were significantly different, p < 0.01 and p = 0.001, respectively. TRACP-5b was negatively correlated with BMD. CONCLUSION: TRACP-5b is not affected by food intake, unlike CTX and PINP. All three BTMs correlate with change in BMD at the lumbar spine and total hip. TRACP-5b has similar diagnostic accuracy to CTX and PINP with commonly used treatments for osteoporosis with the exception of oral bisphosphonate therapy.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Gossiel F, Ugur A, Peel NFA, et al. The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis. Osteoporos Int. 2022. PMID: 35102444. doi:10.1007/s00198-022-06311-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。